Vanguard Group Inc. Purchases 143,584 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Vanguard Group Inc. increased its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,843,740 shares of the biotechnology company's stock after acquiring an additional 143,584 shares during the quarter. Vanguard Group Inc. owned approximately 6.06% of AnaptysBio worth $24,411,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ANAB. Geode Capital Management LLC increased its holdings in shares of AnaptysBio by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company's stock worth $15,594,000 after acquiring an additional 13,336 shares during the period. Victory Capital Management Inc. grew its position in AnaptysBio by 41.0% in the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock worth $4,428,000 after purchasing an additional 97,200 shares during the last quarter. Jennison Associates LLC increased its stake in shares of AnaptysBio by 1.6% in the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company's stock valued at $3,563,000 after purchasing an additional 4,242 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of AnaptysBio by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 166,054 shares of the biotechnology company's stock valued at $2,199,000 after buying an additional 5,733 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of AnaptysBio by 4.8% during the third quarter. Wellington Management Group LLP now owns 65,939 shares of the biotechnology company's stock worth $2,209,000 after buying an additional 3,048 shares during the period.

AnaptysBio Stock Up 7.8 %

AnaptysBio stock traded up $1.49 during mid-day trading on Friday, hitting $20.55. The company's stock had a trading volume of 599,640 shares, compared to its average volume of 591,298. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $41.31. The stock's fifty day moving average price is $17.63 and its two-hundred day moving average price is $20.17. The stock has a market capitalization of $630.21 million, a P/E ratio of -3.38 and a beta of -0.09.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. The business had revenue of $43.11 million during the quarter, compared to analyst estimates of $10.17 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Equities analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has authorized a stock buyback plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its shares are undervalued.

Analyst Ratings Changes

Several analysts have weighed in on the company. HC Wainwright reaffirmed a "neutral" rating and set a $22.00 target price on shares of AnaptysBio in a research note on Tuesday, March 4th. Wolfe Research began coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 target price for the company. JPMorgan Chase & Co. raised their target price on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Guggenheim reaffirmed a "buy" rating on shares of AnaptysBio in a research note on Monday, March 3rd. Finally, Wedbush reiterated an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a research note on Wednesday, February 12th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $33.63.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.